Late hepatitis B reactivation following direct-acting antiviral-based treatment of recurrent hepatitis C in an anti-HBc-positive liver transplant recipient

Julien Vionnet; Manuel Pascual; Barbara Testoni; Christophe Combet; Sébastien Godat; Sandrine Vijgen; Vincent Aubert; Laura Rubbia-Brandt; Fabien Zoulim; Darius Moradpour

doi:10.1002/hep.29528

Late hepatitis B reactivation following direct-acting antiviral-based treatment of recurrent hepatitis C in an anti-HBc-positive liver transplant recipient

Hepatology. 2018 Feb;67(2):791-793. doi: 10.1002/hep.29528. Epub 2018 Jan 4.

Authors

Affiliations

¹ Transplantation Center, Lausanne, Switzerland.
² Service of Gastroenterology and Hepatology as well as, Lausanne, Switzerland.
³ INSERM U1052, Cancer Research Center of Lyon, University of Lyon, Lyon, France.
⁴ Service of Clinical Pathology, University Hospital of Geneva, University of Geneva, Geneva, Switzerland.
⁵ Service of Immunology and Allergy, University Hospital of Lausanne, Lausanne, Switzerland.

PMID: 28921620
DOI: 10.1002/hep.29528

Abstract

Direct-acting antivirals (DAAs) have changed the landscape of hepatitis C virus (HCV) treatment, but chronic hepatitis C (CHC) remains a leading indication for liver transplantation (LT). Hepatitis B virus (HBV) reactivation has been reported in HBV-HCV-coinfected patients treated with DAAs. We report on a case of late HBV reactivation after DAA-based treatment of recurrent hepatitis C in an antibody against hepatitis B core antigen (anti-HBc)-positive LT recipient. (Hepatology 2018;67:791-793).

Publication types

Case Reports

MeSH terms

Antiviral Agents / therapeutic use*
Coinfection / drug therapy
Coinfection / virology
Hepatitis B Antibodies / analysis*
Hepatitis B Core Antigens / immunology*
Hepatitis B virus / physiology*
Hepatitis C, Chronic / drug therapy*
Hepatitis C, Chronic / virology
Humans
Liver Transplantation*
Male
Middle Aged
Recurrence
Virus Activation*

Substances

Antiviral Agents
Hepatitis B Antibodies
Hepatitis B Core Antigens